Pfizer has reported $67.2B in revenue over the last 4 quarters, up 11.2% year-over-year. Net income during this period was $9.4B, representing a 20.9% net margin. However, net income growth has slowed to -1.8% over the last year. The discrepancy between Pfizer's steady revenue growth and slower profit growth suggests the company is facing increased competitive pressures, likely from the loss of exclusivity on some of its key branded drugs. This is a common challenge for large pharmaceutical firms. Pfizer currently pays an annual dividend of $1.60 per share, yielding 3.3% at the current stock price of $48.53. The company has raised its dividend for the past 12 consecutive years. Pfizer's reliable dividend and diversified product portfolio provide some stability, but the company will need to continue investing in its pipeline of new drugs to offset the impact of generic competition on its legacy products. I have a neutral conviction on Pfizer given the mixed signals in the financial data. While Pfizer's revenue growth remains solid, the slowdown in profit expansion is a concern that warrants monitoring. Investors should watch for any signs of further margin pressure or an inability to offset generic headwinds through new product launches. The company's dividend provides some downside protection, but Pfizer's long-term growth will depend on its ability to innovate and bring new drugs to market.

Research these companies